@conference{e4638e4fc2cb4df4a7fcfe0dfe72f0cb,
title = "Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.",
author = "Wen, \{Patrick Y.\} and Michael Castro and Drew Watson and Shweta Kapoor and Ashish Agrawal and Aftab Alam and Roy, \{Kunal Ghosh\} and Swaminathan Rajagopalan and Kabya Basu and Lala, \{Deepak Anil\} and Nirjhar Mundkur and Jim Christie and Anusha Pampana and Sayani Basu and Diwyanshu Sahu and Yugandhara Narvekar and Divya Singh and Prashant Nair and Ahluwalia, \{Manmeet Singh\}",
note = "2017 Background: The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and GBM patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which often yield limited benefit, Cellworks utilizes an individual patient's next generation sequencing results and a mechanistic multi-omics biology model, the Cellworks Omics Biology Model (CBM), to biosimulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells.; Journal of Clinical Oncology ; Conference date: 02-06-2023",
year = "2021",
month = may,
day = "20",
doi = "10.1200/JCO.2021.39.15\_SUPPL.2017",
language = "American English",
}